Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$432000.0.

  • Cartesian Therapeutics' Change in Accured Expenses fell 17297.3% to -$432000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year increase of 6140.47%. This contributed to the annual value of -$6.7 million for FY2024, which is 14415.07% down from last year.
  • Cartesian Therapeutics' Change in Accured Expenses amounted to -$432000.0 in Q3 2025, which was down 17297.3% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Change in Accured Expenses registered a high of $3.2 million during Q2 2022, and its lowest value of -$6.4 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is -$572421.1, with a median of -$432000.0 in 2025.
  • As far as peak fluctuations go, Cartesian Therapeutics' Change in Accured Expenses surged by 71666.67% in 2023, and later crashed by 22277.58% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Change in Accured Expenses stood at -$679000.0 in 2021, then soared by 332.25% to $1.6 million in 2022, then tumbled by 171.21% to -$1.1 million in 2023, then surged by 203.56% to $1.2 million in 2024, then crashed by 137.15% to -$432000.0 in 2025.
  • Its Change in Accured Expenses stands at -$432000.0 for Q3 2025, versus -$2.0 million for Q2 2025 and -$2.2 million for Q1 2025.